Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D Levels and Survival in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03266887
Recruitment Status : Completed
First Posted : August 30, 2017
Last Update Posted : August 30, 2017
Sponsor:
Collaborator:
University of Iceland
Information provided by (Responsible Party):
Icelandic Heart Association

Brief Summary:
Using the population-based data sources in Iceland and the well-characterized AGES-Reykjavik cohort, our overarching aims are on exploring whether pre-diagnostic serum levels of 25-hydroxyvitamin D (25(OH)D) among older individuals living in Iceland were associated with survival after cancer diagnosis. We also wanted to assess the risk of being diagnosed with cancer in association with 25(OH)D levels. In this population living just south of the arctic circle, vitamin D levels largely depend on dietary- and supplemental sources.

Condition or disease
Neoplasms

Layout table for study information
Study Type : Observational
Actual Enrollment : 5764 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Association of Pre-diagnostic Vitamin D Levels and Survival in Older Individuals With Cancer
Actual Study Start Date : January 1, 2002
Actual Primary Completion Date : December 30, 2006
Actual Study Completion Date : December 30, 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D




Primary Outcome Measures :
  1. Overall mortality among cancer patients [ Time Frame: Patients were followed from date of diagnosis since 2002 until death or censored at end of the follow-up (December 31, 2014) ]
    We tested the association between pre-diagnostic 25(OH)D levels and total survival


Secondary Outcome Measures :
  1. Cancer-specific mortality among cancer patients [ Time Frame: Patients were followed from date of diagnosis since 2002 until death or censored at end of the follow-up (December 31, 2014) ]
    We tested the association between pre-diagnostic 25(OH)D levels and cancer survival


Other Outcome Measures:
  1. Pre-diagnostic 25(OH)D levels and cancer risk [ Time Frame: Participants without cancer were followed from the study entry since 2002 until cancer diagnosis, death or end of the observation period whichever occurred first (December 31, 2014) ]
    We tested the association between pre-diagnostic 25(OH)D levels and risk of being diagnosed with cancer


Biospecimen Retention:   Samples With DNA
Serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   66 Years to 98 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
In 1967, all 30,795 men and women living in the capital area of Iceland and born between 1907 and 1935 were invited by the Icelandic Heart Association to join a prospective cohort study. Approximately 19,000 attended the clinic at least once and became participants of the Reykjavik Study. Subsequently, in 2002, a random sample of the cohort comprising 5,764 men and women who were still alive in Iceland and aged 66 to 96 years entered the Ages Gene/Environment Susceptibility (AGES) - Reykjavik Study (20). Serum 25(OH)D was measured in 5,519 of all 5,764 (96%) participants at study entry in year 2002 through 2006.
Criteria

Inclusion Criteria:

To be part of the AGES-Reykjavik Study, initiated between 2002 and 2006.

Exclusion Criteria:

Diagnosed with cancer at study entry

Additional Information:
Layout table for additonal information
Responsible Party: Icelandic Heart Association
ClinicalTrials.gov Identifier: NCT03266887    
Other Study ID Numbers: HI14010102
First Posted: August 30, 2017    Key Record Dates
Last Update Posted: August 30, 2017
Last Verified: August 2017